ArticleEuropean journal of medical research2025
Identification and validation of biomarkers related to mitochondria-associated endoplasmic reticulum membranes in type 2 diabetes mellitus using peripheral blood transcriptomics.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe pathological hallmarks of Type 2 diabetes mellitus (T2DM) are impaired insulin sensitivity and insufficient insulin secretion. As the primary insulin source, pancreatic β-cell decline or dysfunction is key to T2DM progression. Disrupted mitochondria-associated endoplasmic reticulum membranes (MAMs) may compromise β-cell viability and function. This study aimed to identify MAMs-related biomarkers in T2DM pathogenesis.
methodsData were obtained from public databases, and the biomarkers related to MAMs in T2DM were identified by differential expression analysis, WGCNA, supervised machine learning, and expression validation. Subsequently, a nomogram for predicting the prevalence of T2DM was developed, and the performance was evaluated. Additionally, we conducted immune infiltration analysis, GSEA, and molecular docking were performed to analyze the underlying mechanisms of the identified biomarkers. Finally, RT-qPCR was used to further validate the expression trends of these biomarkers.
resultsThree key biomarkers-DUSP26, SLC15A1, and TBX1-were discovered, and the nomogram developed using these markers exhibited strong predictive accuracy for T2DM risk. Interestingly, these biomarkers were predominantly associated with the olfactory transduction pathway and neuroactive ligand-receptor interactions. Additionally, five distinct immune cell types were identified (p < 0.05). Among these, Th2 cells showed the highest positive correlation with activated CD4 T cells (r = 0.45), whereas activated dendritic cells displayed the strongest negative correlation with activated CD4 T cells (r = -0.42). Furthermore, all 3 biomarkers displayed favorable binding abilities with all 3 therapeutic agents for T2DM (< -5.0 kcal/mol), suggesting the potential of biomarkers in the treatment of T2DM. Ultimately, the trend of 3 biomarker expression in the clinical samples was consistent with the GSE184050 and GSE15932, with up-regulated expression, revealing the reliability of biomarker identification.
conclusionThe biomarkers DUSP26, SLC15A1, and TBX1 related to MAMs in T2DM were identified, which supplied a theoretical basis for T2DM-related mechanistic studies and clinical treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.